Telaprevir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='3sv6' size='340' side='right' caption=' | + | <StructureSection load='3sv6' size='340' side='right' caption='Crystal structure of NS3/4A protease in complex with Telaprevir ([[3sv6]])' scene='96/969645/Cv/1'> |
Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir]. | Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir]. | ||
Revision as of 12:40, 11 June 2023
| |||||||||||
